The double-edged sword: Neurotoxicity of chemotherapy
Abstract The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both central and peripheral nervous system toxicities, potentially limiting a patient's ability to tolerate a full course of treatment. Neurot...
Gespeichert in:
| Veröffentlicht in: | Blood reviews 2015-03, Vol.29 (2), p.93-100 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100 |
|---|---|
| container_issue | 2 |
| container_start_page | 93 |
| container_title | Blood reviews |
| container_volume | 29 |
| creator | Magge, Rajiv S DeAngelis, Lisa M |
| description | Abstract The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both central and peripheral nervous system toxicities, potentially limiting a patient's ability to tolerate a full course of treatment. Neurotoxicity with chemotherapy is common and second only to myelosuppression as a reason to limit dosing. This review addresses the neurotoxicity of newly available therapeutic agents including brentuximab vedotin and blinatumomab as well as classic ones such as methotrexate, vinca alkaloids and platinums. Although peripheral neuropathy is common with many drugs, other complications such as seizures and encephalopathy may require more immediate attention. Rapid recognition of adverse neurologic effects may lead to earlier treatment and appropriate adjustment of dosing regimens. In addition, knowledge of common toxicities may help differentiate chemotherapy-related symptoms from actual progression of cancer into the CNS. |
| doi_str_mv | 10.1016/j.blre.2014.09.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5944623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0268960X14000812</els_id><sourcerecordid>1669834601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c580t-183141d85a1fd8cd93c789082f6827f9ba160f580a0e85eb706c193a1f60bc633</originalsourceid><addsrcrecordid>eNp9kcFu1DAURS0EotPCD7BAs2ST8J6TODZClVAFBamCBUViZzn2S8dDJh7spDB_j6MpFbBg5YXPvbbOZewZQomA4uW27IZIJQesS1AlIH_AVthUvEAh8SFbAReyUAK-nrDTlLYAoCrRPmYnvKnrpkW5Ys31htYuzN1ABbkbcuv0I0T3av2R5him8NNbPx3WoV_bDe3CtKFo9ocn7FFvhkRP784z9uXd2-uL98XVp8sPF2-uCttImAqUFdboZGOwd9I6VdlWKpC8F5K3veoMCugzaoBkQ10LwqKqMi2gs6Kqztj5sXc_dztylsYpmkHvo9-ZeNDBeP33zeg3-ibc6kbVteBLwYu7ghi-z5QmvfPJ0jCYkcKcNAqhZFULwIzyI2pjSClSf_8Mgl58661efOvFtwals-8cev7nB-8jvwVn4PURoKzp1lPUyXoaLTkfyU7aBf___vN_4nbwo7dm-EYHStswxzEPoFEnrkF_XhZfBsc6jy1zwS-j6KZ6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1669834601</pqid></control><display><type>article</type><title>The double-edged sword: Neurotoxicity of chemotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Magge, Rajiv S ; DeAngelis, Lisa M</creator><creatorcontrib>Magge, Rajiv S ; DeAngelis, Lisa M</creatorcontrib><description>Abstract The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both central and peripheral nervous system toxicities, potentially limiting a patient's ability to tolerate a full course of treatment. Neurotoxicity with chemotherapy is common and second only to myelosuppression as a reason to limit dosing. This review addresses the neurotoxicity of newly available therapeutic agents including brentuximab vedotin and blinatumomab as well as classic ones such as methotrexate, vinca alkaloids and platinums. Although peripheral neuropathy is common with many drugs, other complications such as seizures and encephalopathy may require more immediate attention. Rapid recognition of adverse neurologic effects may lead to earlier treatment and appropriate adjustment of dosing regimens. In addition, knowledge of common toxicities may help differentiate chemotherapy-related symptoms from actual progression of cancer into the CNS.</description><identifier>ISSN: 0268-960X</identifier><identifier>EISSN: 1532-1681</identifier><identifier>DOI: 10.1016/j.blre.2014.09.012</identifier><identifier>PMID: 25445718</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis Inhibitors - adverse effects ; Angiogenesis Inhibitors - toxicity ; Animals ; Antibodies, Bispecific - adverse effects ; Antibodies, Bispecific - toxicity ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - toxicity ; Brain Diseases - chemically induced ; Brain Diseases - diagnosis ; Brain Diseases - etiology ; Chemotherapy ; Delirium ; Encephalopathy ; Hematologic Neoplasms - complications ; Hematologic Neoplasms - drug therapy ; Hematologic Neoplasms - therapy ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunoconjugates - adverse effects ; Immunoconjugates - toxicity ; Immunotherapy - adverse effects ; Neuropathy ; Neurotoxicity Syndromes - diagnosis ; Neurotoxicity Syndromes - etiology ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - toxicity ; Rituximab - adverse effects ; Rituximab - toxicity ; Seizure ; Seizures - chemically induced ; Seizures - diagnosis ; Seizures - etiology ; Toxicity ; Vinca Alkaloids - adverse effects ; Vinca Alkaloids - toxicity</subject><ispartof>Blood reviews, 2015-03, Vol.29 (2), p.93-100</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c580t-183141d85a1fd8cd93c789082f6827f9ba160f580a0e85eb706c193a1f60bc633</citedby><cites>FETCH-LOGICAL-c580t-183141d85a1fd8cd93c789082f6827f9ba160f580a0e85eb706c193a1f60bc633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0268960X14000812$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25445718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magge, Rajiv S</creatorcontrib><creatorcontrib>DeAngelis, Lisa M</creatorcontrib><title>The double-edged sword: Neurotoxicity of chemotherapy</title><title>Blood reviews</title><addtitle>Blood Rev</addtitle><description>Abstract The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both central and peripheral nervous system toxicities, potentially limiting a patient's ability to tolerate a full course of treatment. Neurotoxicity with chemotherapy is common and second only to myelosuppression as a reason to limit dosing. This review addresses the neurotoxicity of newly available therapeutic agents including brentuximab vedotin and blinatumomab as well as classic ones such as methotrexate, vinca alkaloids and platinums. Although peripheral neuropathy is common with many drugs, other complications such as seizures and encephalopathy may require more immediate attention. Rapid recognition of adverse neurologic effects may lead to earlier treatment and appropriate adjustment of dosing regimens. In addition, knowledge of common toxicities may help differentiate chemotherapy-related symptoms from actual progression of cancer into the CNS.</description><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Angiogenesis Inhibitors - toxicity</subject><subject>Animals</subject><subject>Antibodies, Bispecific - adverse effects</subject><subject>Antibodies, Bispecific - toxicity</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Brain Diseases - chemically induced</subject><subject>Brain Diseases - diagnosis</subject><subject>Brain Diseases - etiology</subject><subject>Chemotherapy</subject><subject>Delirium</subject><subject>Encephalopathy</subject><subject>Hematologic Neoplasms - complications</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunoconjugates - adverse effects</subject><subject>Immunoconjugates - toxicity</subject><subject>Immunotherapy - adverse effects</subject><subject>Neuropathy</subject><subject>Neurotoxicity Syndromes - diagnosis</subject><subject>Neurotoxicity Syndromes - etiology</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Organoplatinum Compounds - toxicity</subject><subject>Rituximab - adverse effects</subject><subject>Rituximab - toxicity</subject><subject>Seizure</subject><subject>Seizures - chemically induced</subject><subject>Seizures - diagnosis</subject><subject>Seizures - etiology</subject><subject>Toxicity</subject><subject>Vinca Alkaloids - adverse effects</subject><subject>Vinca Alkaloids - toxicity</subject><issn>0268-960X</issn><issn>1532-1681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAURS0EotPCD7BAs2ST8J6TODZClVAFBamCBUViZzn2S8dDJh7spDB_j6MpFbBg5YXPvbbOZewZQomA4uW27IZIJQesS1AlIH_AVthUvEAh8SFbAReyUAK-nrDTlLYAoCrRPmYnvKnrpkW5Ys31htYuzN1ABbkbcuv0I0T3av2R5him8NNbPx3WoV_bDe3CtKFo9ocn7FFvhkRP784z9uXd2-uL98XVp8sPF2-uCttImAqUFdboZGOwd9I6VdlWKpC8F5K3veoMCugzaoBkQ10LwqKqMi2gs6Kqztj5sXc_dztylsYpmkHvo9-ZeNDBeP33zeg3-ibc6kbVteBLwYu7ghi-z5QmvfPJ0jCYkcKcNAqhZFULwIzyI2pjSClSf_8Mgl58661efOvFtwals-8cev7nB-8jvwVn4PURoKzp1lPUyXoaLTkfyU7aBf___vN_4nbwo7dm-EYHStswxzEPoFEnrkF_XhZfBsc6jy1zwS-j6KZ6</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Magge, Rajiv S</creator><creator>DeAngelis, Lisa M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150301</creationdate><title>The double-edged sword: Neurotoxicity of chemotherapy</title><author>Magge, Rajiv S ; DeAngelis, Lisa M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c580t-183141d85a1fd8cd93c789082f6827f9ba160f580a0e85eb706c193a1f60bc633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Angiogenesis Inhibitors - toxicity</topic><topic>Animals</topic><topic>Antibodies, Bispecific - adverse effects</topic><topic>Antibodies, Bispecific - toxicity</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Brain Diseases - chemically induced</topic><topic>Brain Diseases - diagnosis</topic><topic>Brain Diseases - etiology</topic><topic>Chemotherapy</topic><topic>Delirium</topic><topic>Encephalopathy</topic><topic>Hematologic Neoplasms - complications</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunoconjugates - adverse effects</topic><topic>Immunoconjugates - toxicity</topic><topic>Immunotherapy - adverse effects</topic><topic>Neuropathy</topic><topic>Neurotoxicity Syndromes - diagnosis</topic><topic>Neurotoxicity Syndromes - etiology</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Organoplatinum Compounds - toxicity</topic><topic>Rituximab - adverse effects</topic><topic>Rituximab - toxicity</topic><topic>Seizure</topic><topic>Seizures - chemically induced</topic><topic>Seizures - diagnosis</topic><topic>Seizures - etiology</topic><topic>Toxicity</topic><topic>Vinca Alkaloids - adverse effects</topic><topic>Vinca Alkaloids - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magge, Rajiv S</creatorcontrib><creatorcontrib>DeAngelis, Lisa M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magge, Rajiv S</au><au>DeAngelis, Lisa M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The double-edged sword: Neurotoxicity of chemotherapy</atitle><jtitle>Blood reviews</jtitle><addtitle>Blood Rev</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>29</volume><issue>2</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><issn>0268-960X</issn><eissn>1532-1681</eissn><abstract>Abstract The number of available therapies for hematologic malignancies continues to grow at a rapid pace. Unfortunately, many of these treatments carry both central and peripheral nervous system toxicities, potentially limiting a patient's ability to tolerate a full course of treatment. Neurotoxicity with chemotherapy is common and second only to myelosuppression as a reason to limit dosing. This review addresses the neurotoxicity of newly available therapeutic agents including brentuximab vedotin and blinatumomab as well as classic ones such as methotrexate, vinca alkaloids and platinums. Although peripheral neuropathy is common with many drugs, other complications such as seizures and encephalopathy may require more immediate attention. Rapid recognition of adverse neurologic effects may lead to earlier treatment and appropriate adjustment of dosing regimens. In addition, knowledge of common toxicities may help differentiate chemotherapy-related symptoms from actual progression of cancer into the CNS.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25445718</pmid><doi>10.1016/j.blre.2014.09.012</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-960X |
| ispartof | Blood reviews, 2015-03, Vol.29 (2), p.93-100 |
| issn | 0268-960X 1532-1681 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5944623 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - toxicity Animals Antibodies, Bispecific - adverse effects Antibodies, Bispecific - toxicity Antineoplastic Agents - adverse effects Antineoplastic Agents - toxicity Brain Diseases - chemically induced Brain Diseases - diagnosis Brain Diseases - etiology Chemotherapy Delirium Encephalopathy Hematologic Neoplasms - complications Hematologic Neoplasms - drug therapy Hematologic Neoplasms - therapy Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunoconjugates - adverse effects Immunoconjugates - toxicity Immunotherapy - adverse effects Neuropathy Neurotoxicity Syndromes - diagnosis Neurotoxicity Syndromes - etiology Organoplatinum Compounds - adverse effects Organoplatinum Compounds - toxicity Rituximab - adverse effects Rituximab - toxicity Seizure Seizures - chemically induced Seizures - diagnosis Seizures - etiology Toxicity Vinca Alkaloids - adverse effects Vinca Alkaloids - toxicity |
| title | The double-edged sword: Neurotoxicity of chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T12%3A37%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20double-edged%20sword:%20Neurotoxicity%20of%20chemotherapy&rft.jtitle=Blood%20reviews&rft.au=Magge,%20Rajiv%20S&rft.date=2015-03-01&rft.volume=29&rft.issue=2&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.issn=0268-960X&rft.eissn=1532-1681&rft_id=info:doi/10.1016/j.blre.2014.09.012&rft_dat=%3Cproquest_pubme%3E1669834601%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1669834601&rft_id=info:pmid/25445718&rft_els_id=1_s2_0_S0268960X14000812&rfr_iscdi=true |